Table 1.

Demographic and clinical characteristics of Study Cohort

Factor	Cholangiocarcinoma (CCA) N=11	Primary Sclerosing Cholangitis (PSC) N=21	p- value (PSC VS CCA)
Male, N (%)	7(63.6%)	11(52.4%)	0.71
Caucasian, N (%)	9(81.8%)	17(85%)	0.53
Body mass index, Mean (SD)	27.26(9.5)	25.1(5.0)	0.97
Albumin median [interquartile range] (g/dL)	3.4(2.9–4.4)	3.5(3.0–4.1)	0.77
Bilirubin median [interquartile range] (mg/dL)	2.2(0.8–10.3)	1.8(0.5–3.4)	0.41
Concomitant Inflammatory bowel disease (IBD)	2 (18.2%)	12 (57.1%)	0.03
Current Smoking	3 (27.3%)	3 (14.3%)	0.39
Current alcohol use	2 (18.2%)	1 (4.8%)	0.27
Distribution of PSC
Intrahepatic	0	4 (19%)
Extrahepatic	2 (18.2%)	4 (19%)	0.10
Both	9 (81.8%)	13 (61.9%)
Alkaline phosphatase median [interquartile range] (U/L)	414(225.5–709.5)	227.5(154.8–475.5)	0.27
Aspartate aminotransferase median [interquartile range] (U/L)	93(26.5–127)	75.5(32.3–101)	0.74
Alanine aminotransferase median [interquartile range] (U/L)	89(34.5–107.5)	58(40–113)	0.91
Carbohydrate antigen 19-9 (CA 19-9), U/L, mean (SD)	250.2 (114.6)	162.6 (58.1)	0.14